Photocure appoints Torbjørn Øye interim CFO
This article was originally published in Scrip
Specialty pharmaceutical company Photocure, which focuses on photodynamic technologies in dermatology and cancer, has made Torbjørn Øye interim chief financial officer following the departure of Christian Fekete on 1 December 2011. Mr Fekete resigned after serving as Photocure's CFO since 2004. Mr Øye joins the company from Uniconsult and has a wide range of experience within financial and accounting departments of various companies.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.